Aurora cannabis and vectura fertin pharma, inc. announce commercial collaboration

Aurora cannabis and vectura fertin pharma, inc. announce commercial collaboration collaboration will initially see launch of a new cbd lozenge from cogent international, a vectura fertin pharma subsidiary, on aurora's canadian medical cannabis patient platform following successful launch of cbd lozenge, the collaboration will explore the potential to launch vectura fertin pharma's future medical cannabis portfolio in canada edmonton, ab, and stamford, ct – august 1, 2024 - aurora cannabis inc. ("aurora") (nasdaq | tsx: acb), a leading canadian-based global medical cannabis company, and vectura fertin pharma, inc., an innovator in wellness and healthcare, are pleased to announce that aurora has entered into a commercial collaboration with cogent international manufacturing ltd. (“cogent”), a wholly-owned subsidiary of vectura fertin pharma inc. through this arrangement, cogent will initially launch its newly developed cbd lozenge on aurora's canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis.
ACB Ratings Summary
ACB Quant Ranking